Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Paper talk: new drug for skin cancer; swine flu linked to narcolepsy; new molecule for breast cancer

The first new treatment for advanced skin cancer since the 1970s has been granted licensing approval by the European Medicine Agency, the Telegraph reports. However, The drug, ipilimumab, is still under review by Nice so is not widely available on the NHS. Following reports earlier this year that the swine flu vaccine could lead to narcolepsy, the Telegraph writes that the virus itself could trigger the rare sleeping disorder. The Independent writes that a naturally occuring molecule in bacteria can block the development of breast cancer. NHS waiting times are soaring, the Guardian writes, with doctors blaming hospital budget cuts, saying the NHS is "going backwards under the Tories". The Telegraph reports that Edzard Enrst, a professor of complementary medicine, is on a crusade to stop the NHS wasting money on unproven remedies. The Guardian reports that the NHS is to issue new advice after a kidney transplant patient received organs from a donor with cancer. Women gain weight after marriage, the Telegraph reports, while men pile on the pounds after a divorce. The Telegraph's James LeFanu looks at how the outlook for prostate cancer sufferers is getting better.  

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD014439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel